Bluejay Diagnostics, Inc. (BJDX)

US — Healthcare Sector
Peers: TIVC  VTAK  WINT  UPC  BCTXZ  MLEC  MSPR  ELAB  NKGN  WGS 

Automate Your Wheel Strategy on BJDX

With Tiblio's Option Bot, you can configure your own wheel strategy including BJDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
BJDX
Published: October 09, 2025 by: GlobeNewsWire
Sentiment: Neutral

ACTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,250,000 shares of common stock (or pre-funded warrant in lieu thereof) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The …

Read More
image for news Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

About Bluejay Diagnostics, Inc. (BJDX)

  • IPO Date 2021-11-10
  • Website https://bluejaydx.com
  • Industry Medical - Devices
  • CEO Indranil Dey
  • Employees 7
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.